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 Abstract.  The Republic of Korea (ROK) Army instituted a vivax malaria chemoprophylaxis program (hydroxychlo-
roquine [HCQ] 400 mg per week) in 1997 that was expanded to nearly 200,000 soldiers by 2007, raising concerns for the 
emergence of drug-resistant vivax malaria. Therefore, a study of whole blood HCQ concentrations for all malaria patients 
admitted to four ROK Army hospitals was conducted from June through September 2007. For all 142 vivax malaria 
patients enrolled, fevers returned to normal by Day 3 post-treatment and all thin blood films were negative for parasites 
by Day 7. Pre-treatment whole blood concentrations of HCQ for 14 patients were > 100 ng/mL. Eight of the patients were 
enrolled in the ROK Army chemoprophylaxis program that reported taking HCQ as directed, with the last pill taken ≥ 4 
days before diagnosis. Although there was no evidence of clinical resistance, chemoprophylaxis data indicates the biologi-
cal resistance or tolerance to HCQ in ROK. 
 INTRODUCTION 
 Chloroquine (CQ) has been the treatment of choice for vivax 
malaria for more than 40 years with no alternative chemother-
apy comparable in efficacy, safety, and cost. 1,2 Chloroquine-
resistant  P. vivax (CRPV) malaria, reported in Papua New 
Guinea, India, Burma, Guyana, and Indonesia, poses a seri-
ous health threat to millions of people who reside or travel 
to vivax malaria endemic regions of high incidence and long 
transmission periods. 3,4 The reemergence of  Plasmodium 
vivax in the Republic of Korea (ROK) was reported in 1993 
along the demilitarized zone (DMZ) and became endemic in 
this area, whereas there have been no autochthonous trans-
mission reports of  P. falciparum ,  Plasmodium malariae , or 
 Plasmodium ovale malaria. 5,6 Malaria transmission occurs 
from late April through October with the first cases present-
ing in late May/June through early November with sporadic 
cases occurring from November through May as a result of 
latent malaria transmitted during the previous malaria sea-
son. 7–9 Nearly all transmission has been attributed to exposure 
in northern Gyeonggi and northwestern Gangwon Provinces 
near the DMZ that separates the ROK and North Korea and 
where many ROK Army personnel are stationed. 6,9 Because 
of its strategic and geographic distribution, 7 relatively large 
numbers of ROK soldiers contract vivax malaria annually. 
To address this problem, the ROK Army instituted a chemo-
prophylaxis program (hydroxychloroquine [HCQ] 400 mg 
2 weeks before the onset of the malaria season and weekly 
thereafter through mid October followed by terminal chemo-
prophylaxis with primaquine, 15 mg daily/14 days) for per-
sonnel assigned to units located in malaria high-risk areas 
(malaria incidence > 10/100,000) near the DMZ. The program 
was initiated in 1997 with approximately 16,000 ROK soldiers 
placed on chemoprophylaxis and has been expanded annually 
to include nearly 200,000 ROK soldiers by 2007. Although it 
is suggested that this program contributed to the reduction of 
malaria cases from 2000 to 2004, 10 it is difficult to assess the 
effectiveness of this program because the number of malaria 
cases increased in 2005–2007 when the malaria chemopro-
phylaxis program was expanded. 8 Although CRPV has not 
been confirmed since the implementation of the ROK Army 
chemoprophylaxis program, there is much concern regard-
ing potential breakthroughs as suggested by soldiers devel-
oping malaria while taking chemoprophylaxis as directed. 
Additionally, extensive use of chemoprophylaxis may serve to 
hasten the development of drug resistance when drug plasma 
concentrations, caused by non-compliance or other factors, are 
not high enough to kill circulating parasites. Therefore, confir-
mation of  P. vivax HCQ resistance is necessary to address this 
potential significant health threat in the ROK. In this study, 
we investigated potential chemotherapy failures and evalu-
ated clinical resistance in ROK Army soldiers that developed 
malaria during the 2007 malaria season. 
 MATERIALS AND METHODS 
 Volunteer patients.  All ROK Army soldiers admitted to 
the Armed Forces Capital Hospital, Armed Forces Yangju 
Hospital, Armed Forces Ildong Hospital, or Armed Forces 
Byukjae Hospital with a history of fever within 48 hours 
and microscopically confirmed malaria from June through 
September 2007 were prospectively enrolled. These four 
ROK military hospitals are the primary health care facilities 
for treatment of malaria for all ROK soldiers assigned to 
the Seoul Metropolitan Area and Gyeonggi Province where 
more than one-half of all ROK soldiers in malaria-endemic 
areas were stationed. The ROK soldiers assigned to units in 
601BIOLOGICAL RESISTANCE OF VIVAX MALARIA IN KOREA
malaria-risk areas remained in the same location throughout 
the study period and were admitted to one of the four primary 
health care hospitals when medical providers at local military 
health clinics suspected malaria. Upon hospital admission 
from June through September 2007, venous blood was drawn 
(pre-treatment, Day 0 [D0]), thin blood films prepared, and 
if positive for vivax malaria parasites, patients were included 
under an approved human use protocol (Ethics Committee, 
Armed Forces Medical Command, Seoul, Korea) as part of 
the malaria surveillance program in Korea. All ROK Army 
soldiers admitted to one of the four hospitals with malaria 
were ≥ 19 years of age. Patients were excluded from the study 
if they were diagnosed and treated for malaria within 30 days 
at local military health clinics before hospital admission or if 
they elected not to participate in the study. Additional venous 
blood samples of vivax malaria patient volunteers were drawn 
on D2, D3, and D7, post-treatment, following informed consent 
for each blood draw. All venous blood samples were used for 
blood film preparation and blood spots dried on filter paper 
for measuring whole blood levels of total hydroxychloroquine 
(THCQ) . THCQ is comprised of both hydroxychloroquine 
and its active metabolite, desethylhydroxychloroquine. A 
question naire of patient history, including chemoprophylaxis 
usage (compliance), was completed by each volunteer on D0 
after informed consent. 
 Patients were given a total of 2,000 mg hydroxychloroquine 
(HCQ; Korean United Pharmaceutical Inc., Seoul, Republic 
of Korea); 800 mg at 0 hr after diagnosis, 400 mg at 6 hr, 400 mg 
at 24 hr, and 400 mg at 48 hr, followed by 15 mg primaquine 
(Myung In Pharmaceutical, Seoul, Republic of Korea) daily 
for 14 days. Patients remained hospitalized for 7 days after 
diagnosis and each treatment dosage during that period was 
supervised and documented by the nursing staff during admis-
sion, with the remaining terminal primaquine regimens pro-
vided as an outpatient (undocumented) from Days 8–16 after 
initial treatment. 
 Microscopic examination of blood films.  Thin blood films 
were prepared from venous blood in accordance with standard 
laboratory practice. Blood films were stained with Giemsa 
for 30 min at pH 7.2, air-dried, and slides reviewed by two 
pathologists who examined at least 200 fields at 1000×. Positive 
slides were defined as those with asexual stages (trophozoites/
merozoites and schizonts) present in the thin blood films. 
 Hydroxychloroquine (HCQ) blood concentrations.  Whole 
blood levels of HCQ and its active metabolite DHCQ were 
measured for malaria patients who were enrolled in the ROK 
Army chemoprophylaxis program. Whole blood (100 μL) 
collected from venous blood at D0 pre-treatment were blotted 
on filter paper (No. 1 Whatman, Fairfield, NJ). Filter paper 
blood spots were air-dried and stored in ziplock plastic bags at 
room temperature until analyzed. Blood level concentrations 
(ng/mL) were reported as THCQ (HCQ + DHCQ). 
 High-performance liquid chromatography (HPLC) was used 
to determine whole blood levels of HCQ and its active metab-
olite DHCQ. Hydroxychloroquine and DHCQ were extracted 
from filter paper using a liquid–liquid extraction technique. 
Analytical separation was achieved with a reverse-phase C18 
column (4.6 × 150 mm, 5 μm; XTerra; Waters Corporation, 
Milford, MA) using a mobile phase consisting of 40% ace-
tonitrile and 60% water containing 1% diethylamine at a flow 
rate of 1 mL/min. The analytes were detected using fluores-
cence with excitation and emission wavelength set to 330 and 
380 nm, respectively. Standard curve samples were prepared 
by spiking whole blood at the following concentrations of 
HCQ and DHCQ: 0, 50, 100, 250, 500, and 1,000 ng/mL. The 
spiked blood (0.1 mL) was applied to filter paper and allowed 
to air-dry before extraction. Interassay precision (expressed as 
coefficient of variation [CV]) and accuracy (CV) were deter-
mined for both analytes. For nine standard curve runs (nine 
separate days), the precision (CV) was determined to be 42%, 
23%, 11%, 13%, and 3% for HCQ and 40%, 17%, 11%, 14%, 
and 3% for DHCQ at concentrations of 50, 100, 250, 500, and 
1,000 ng/mL, respectively. Interassay accuracy (CV) was 0%, 
2.9%, 4.5%, and −1.4% for HCQ and 0.6%, 4.9%, 1.4%, and 
−0.6% for DHCQ respective to the concentrations stated pre-
viously. The limits of detection (3 × standard deviation of cal-
culated baseline values) obtained for this assay were 67 and 
38 ng/mL for HCQ and DHCQ, respectively. 
 Biological resistance was defined if the pre-drug level of 
THCQ whole blood level was > 100 ng/mL when patients 
self-administered chemoprophylaxis ≥ 4 days before vivax 
malaria diagnosis. 11,12 Suspected biological resistance was de-
fined as pre-treatment whole blood concentrations of THCQ 
of > 100 ng/mL when patients self-administered chemopro-
phylaxis irregularly or within 3 days before diagnosis. Clinical 
resistance was defined if persistent parasitemia was demon-
strated in blood films on D7 post-treatment or if soldiers pre-
sented with malaria within 28 days post-treatment. 
 RESULTS 
 A total of 142 ROK Army male soldiers presenting with 
vivax malaria were enrolled (informed consent) in the study 
on D0 with a median age of 21years (range 19–50 years), but 
by D7, only 108 of the malaria patients participated in the 
study ( Figure 1 ) . All patients had symptoms (e.g., recurrent 
fever, chills, and headache), with 128 (90.1%) showing fever at 
the time of admission. A total of 135 (95.1%) patients showed 
thrombocytopenia and none of the patients needed redosing 
during treatment because of drug side effects (e.g., vomiting 
 Figure 1.  The number (percent) of patients with vivax malaria 
positive blood films, pre- and post-treatment with hydroxychloro-
quine. * The number of patients throughout the study: D0 = 142, D2 = 
118, D3 = 117, D7 = 108. 
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within an hour after medication) ( Table 1 ) . For all 142 patients, 
temperatures returned to normal by D3 post-treatment. By 
D2 and D3, only 17.8% (21/118) and 6.0% (7/117), respec-
tively, demonstrated parasites in their blood films ( Figure 1 ). 
By D7, vivax malaria parasites were cleared from all patients 
examined (108/108). None of the patients reported for medi-
cal treatment of vivax malaria symptoms (e.g., fever, headache, 
and chills) within 28 days post-treatment. 
 A total of 10.6% (15/142) malaria patients enrolled in the 
study were not enrolled in the mandatory chloroquine/pri-
maquine ROK Army chemoprophylaxis program for malaria 
high-risk areas, while 89.4% (127/142) were enrolled. A total 
of 14 (11.0%) patients had whole blood THCQ pre-treatment 
levels > 100 ng/mL and were classified as biological resistance 
(8) or suspected biological resistance (6), as defined previo-
iusly. Hydroxychloroquine and DHCQ were not detected in 
58.3% (74/127) of the patients ( Table 2 ) . The ratio of HCQ/
DHCQ for 8 patients classified as biological resistance ranged 
from 0.9 to 22.8 ( Table 3 ) . 
 DISCUSSION 
 This is the first clinical trial designed to identify HCQ-
resistant vivax malaria using whole blood HCQ concentra-
tions for soldiers diagnosed with  P. vivax in the ROK. The 
study showed that some of the ROK Army soldiers admitted 
with malaria had high HCQ concentrations suggesting either 
an intrinsic, reduced susceptibly to HCQ, or biological resis-
tance, all of which may be manifest as clinical resistance. This 
 in vivo test on the use of HCQ for the treatment and prophy-
laxis of  P. vivax , also showed chemoprophylaxis failures. This 
study shows evidence of biological resistance in at least eight 
ROK Army soldiers based on THCQ whole blood levels and 
patient chemoprophylaxis history, but may also reflect the 
vivax malaria situation in North Korea 13 based on the poten-
tial for the introduction of vivax malaria-infected mosquitoes 
along the DMZ or malaria infections through South Korean 
laborers working in Kaesong, North Korea. 11 
 The whole blood concentration of CQ plus DHCQ to cure 
CQ-sensitive vivax malaria blood parasites is considered > 100 
ng/mL over 4 days, 11,12,14–16 although determining the therapeutic 
range of CQ against  P. vivax is problematic. 17 The ratio of 
molecular weight of HCQ/CQ is 1.05 and thus similar mini-
mal effective concentrations can be applied to HCQ. In this 
study, 14 (11.0%) of the malaria patients had THCQ levels 
> 100 ng/mL and eight patients where parasites were estimated 
to be exposed to HCQ of higher than minimal effective con-
centration for ≥ 4 days at initial presentation. This  sug gests 
the presence of biological resistant vivax malaria parasites 
in the ROK. The CRPV is usually reported in high-burden 
and endemic areas where large amounts of CQ has been pre-
scribed for considerable duration. 3,4,14,18 In these areas, biologi-
cal resistance rates are much higher compared with our data, 
with previous studies in Papua New Guinea and Indonesia 
that reported biological resistance levels as high as and 53% 18 
and 73%, 19 respectively, and where chloroquine is no lon-
ger effective for treatment or chemoprophylaxis for  P. vivax 
blood infections. Considerations of costs and health bene-
fits for continued extensive use of chemoprophylaxis in the 
ROK Army that may lead to the emergence of clinical resis-
tant vivax malaria among the ROK Army and civilian compo-
nents are necessary. 18,20,21 Perhaps a more limited application 
with observed compliance policies may be more effective for 
defined malaria high-risk areas that may reduce increased 
risks of drug resistance. 
 Hydroxychloroquine clinical-resistant vivax malaria was 
not observed, as febrile symptoms subsided within 3 days. 
Although 6.0% of the thin smears were positive on D3, post-
treatment, all thin smears were negative on D7. This slow 
clearance may indicate the beginning of drug resistance to 
HCQ. 22,23 Although CQ can have a antipyretic effect, 24 none 
of the volunteers were readmitted to the hospital for fever 
within 28 days after therapeutic medication, except for one 
patient that was diagnosed with malaria (relapse) 31 days 
post-treatment. In this case, a recurrence of malaria cannot  Table 1 
Patient characteristics at enrollment ( N = 142) 
Median age (range), years 21 (19–50)
Male (%) 142 (100)
No. patients symptomatic* 142 (100)
No. with fever† (%) 128 (90.1)
Complete blood count
Mean white blood cell (SD‡)/mm3 4,748 (1699)
Mean hemoglobin (SD‡) g/dL 13.6 (1.4)
Mean platelet (SD‡) 77.4 (66.3)
No. with thrombocytopenia (%)§ 135 (95.1)
Side effects of treatment
No. (%) with abdominal discomfort 11 (7.7)
No. (%) with diarrhea 7 (4.9)
No. (%) with nausea or vomiting 4 (2.8)
No. (%) with redosing because of side effects 0 (0)
 * Defined as febrile, chills, headache, and/or myalgia. 
 † Defined as axillary temperature ≥ 37.3°C. 
 ‡ Standard deviation. 
 § Defined as < 150,000 cells/mm 3 . 
 Table 3 
The whole blood concentrations of total hydroxychloroquine for eight 
malaria patients with THCQ pre-drug levels > 100 ng/mL at D0 (pre-
treatment) and that also reported chemoprophylaxis compliance* 
Patient no.
Drug level concentrations (ng/mL)
HCQ/DHCQHCQ DHCQ THCQ
1 359.5 38.5 398.0 9.3
2 371.8 17.8 389.6 20.9
3 133.5 143.1 276.6 0.9
4 151.0 26.0 177.0 5.8
5 127.1 16.5 143.6 7.7
6 101.6 8.2 109.8 12.4
7 96.1 10.0 106.1 9.6
8 100.8 4.4 105.2 22.8
 * HCQ = hydroxychloroquine; DHCQ = desethylhydroxychloroquine; THCQ = total 
hydroxychloroquine (HCQ + DHCQ) . 
 Table 2
 The distribution of pre-treatment whole blood total hydroxychloro-
quine (hydroxychloroquine + desethylhydroxychloroquine) levels 
for malaria patients in the mandatory ROK Army chemoprophy-
laxis program 
Total hydroxychloroquine (ng/mL) Number of patients (%)
0 74 (58.3)
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be ruled out, especially with the anti-blood stage mode of 
action of primaquine. 25 However, as the patient was in non-
compliance with terminal primaquine prophylaxis, this is 
highly suggestive that this is recrudescence caused by latent 
liver stage parasites. In a previous report, 2/86 patients that 
had recurrent malaria, demonstrated by  P. vivax positive thin 
blood films and polymerase chain reaction (PCR)-based 
assays 14 days after medication, were successfully treated 
after additional therapy with the same regimen. 26 These cases 
were most likely a result of primaquine failure at doses of 15 
mg for 14 days rather than HCQ failure. 27,28 Although there 
have been no reports showing clinical resistance to vivax 
malaria to CQ or HCQ in the ROK, 17.8% of patients on 
D2 and 6.0% on D3 post-treatment showed asexual para-
sites in thin blood films. This slow parasite clearance could be 
an important early clue to the development of clinical resis-
tance, showing the need for a malaria surveillance program 
that includes clinical resistance to identify the minimal effec-
tive concentrations of THCQ. 29 
 Hydroxychloroquine resistance is the main consideration 
for the chemoprophylaxis protocol. A prematurely termi-
nated program can be one of the major causes of chemopro-
phylaxis failure, especially in military personnel. 30 Tolerability 
and efficacy vary between drugs. 31,32 In the ROK Army, HCQ 
is currently an effective prophylactic regimen because the 
number of malaria patients showing HCQ resistance are rela-
tively low compared with the military personnel enrolled in 
the chemoprophylaxis program. However, the continued high 
usage or expansion of HCQ may lead to increased risks of 
chemoprophylaxis or clinical failures caused by parasite toler-
ance or resistance, especially where chemoprophylaxis is not 
carefully monitored to ensure proper dosage. Thus, studies 
need to be implemented that monitor blood level concentra-
tions of HCQ among ROK Army soldiers on chemoprophy-
laxis and those developing malaria to identify early drug 
resistant trends. 
 This study has several limitations. First, only a thin smear 
was examined and this could have affected the decision of 
clinical resistance because thin blood films are not as sensi-
tive as thick blood films for identification of low parasitemia 
levels. However, only one patient was readmitted for malaria 
(D31, post-treatment), which was most likely a result of 
incomplete terminal primaquine treatment. In addition, two 
experienced pathologists observed more than 200 high-power 
fields on at least two slides before considering slides nega-
tive for malaria parasites. 33 All of the enrolled patients had 
improved febrile symptoms after treatment, and none pre-
sented again with malaria within 28 days. Second, medication 
history depended on patients’ memory. As patient identifi-
ers were removed and questionnaires were anonymous with 
no retribution for non-compliance, the assumption was that 
the soldiers responded honestly to the questions regarding 
chemoprophylaxis compliance. Furthermore, we checked to 
determine if patient medication histories were in agreement 
with chemoprophylaxis program schedules for each military 
unit because soldiers usually took the medication on the same 
day of each week. However, this may be in error as 62.2% 
(46/74) soldiers indicated that they had taken hydroxychloro-
quine chemoprophylaxis weekly as directed, but did not show 
THCQ in their blood on admission at D0 before taking medi-
cation. Thus, a study that includes weekly “observed” compli-
ance and weekly THCQ blood levels that shows the range of 
THCQ concentrations is justified. Despite this limitation, all 
eight patients showed biological resistance based on THCQ 
concentrations of 105 to 398 ng/mL, which indicated they 
had taken medication 2–7 days before hospital admission. 34 
We also reconfirmed unit medication schedules for the eight 
patients that they were not given prophylactic medication on 
the same day of admission. Third, there is no data for Korean 
pharmacokinetics of CQ or HCQ and therefore data were 
correlated with previous reports elsewhere. Fourth, the cut-
off of 7 days would only detect high grade parasite resistance 
and cases of recurrent parasitaemia after D7 could be missed. 
Finally, the use of primaquine, with its antiblood stage activ-
ity against vivax, also could limit the ability to define clinical 
resistance because CQ-resistant parasites might be subpatent 
because of primaquine. 35 
 In conclusion, chemoprophylaxis data shows the potential 
for vivax malaria resistance or tolerance to HCQ when taken 
at 400 mg weekly in the ROK. To prevent the emergence of 
clinical resistance, careful consideration for the pros and cons 
for the use of extensive chemoprophylaxis is required. 
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